Cielo vs Vytora Health
Two GLP-1 desks, one scoreboard. We put Cielo and Vytora Health head-to-head on the published Brief Score — the same six factors, scored the same way.
Vytora Health
The verdict
Vytora Health takes this head-to-head.
Vytora Health scores 87 to 69 on our six-factor Brief Score — A rare accredited desk that pairs brand-name access with fair mid-market compounded pricing across all 50 states.
That doesn't make Cielo a bad call — it's best for readers who want flat-rate compounded glp-1 at the lowest 3-month bundle prices. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Cielo | Vytora Health | |
|---|---|---|
| Brief Score | 69/100 (C) | 87/100 (B+) |
| Semaglutide | From $149/mo (all doses, compounded) | $150/mo |
| Tirzepatide | From $249/mo (all doses, compounded) | $200/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
Cielo: New to the tracker on 1 August 2026. The published line reads From $149/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
Vytora Health: $150 sema / $200 tirz nationwide; LegitScript-certified with brand-name access.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.